deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04656418

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema

Sponsor: CSL Behring

Conditions Hereditary Angioedema
Interventions CSL312 Placebo
Updated 24 times since 2021 Last updated: Jun 7, 2023 Started: Jan 27, 2021 Primary completion: Jun 7, 2022 Completion: Jun 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hereditary Angioedema, this trial is completed. The trial is conducted by CSL Behring and has accumulated 24 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2023 — Jul 2023 [monthly]

    Completed PHASE3

▶ Show 19 earlier versions

  1. Dec 2022 — Feb 2023 [monthly]

    Completed PHASE3

  2. Sep 2022 — Dec 2022 [monthly]

    Completed PHASE3

  3. Jul 2022 — Sep 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  5. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2022 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  10. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  11. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  12. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  13. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  14. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  15. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  16. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  17. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  18. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE3

  19. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CSL Behring
Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ashkelon, Israel , Berlin, Germany , Birmingham, United States , Budapest, Hungary , Bunkyo, Japan , Chevy Chase, United States , Cincinnati, United States , Dallas, United States , Edmonton, Canada and 17 more locations